HAE HAEMONETICS CORP

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Medical devices and technologies for plasma collection, blood centers, and hospitals
• • Emphasis on Plasma and Hospital segments as primary growth drivers; Blood Center focused on targeted plasma and platelet opportunities

Risk Factors

• • Regulatory risk from SEC Rule 10b5-1 affecting timing and execution of $500M share repurchase program through April 2028
• • Share repurchase program could increase stock price volatility and reduce market liquidity for common stock

Management Discussion & Analysis

• • Revenue $1.361B, up 4.0% YoY; Hospital segment up 23.7% ($564M vs $456M), Plasma down 6.0% ($535M vs $570M), Blood Center down 7.8% ($261M vs $283M)
• • Operating margin 16.3% vs 12.6%; gross margin 55.0% vs 52.8%; net income margin 12.3% vs 9.0%

Risk Factors

• • Newly added geopolitical risk: heightened tensions in China, Taiwan, Russia, Ukraine, and the Middle East affecting operations
• • Most materially updated operational risk: supply chain disruptions due to climate change, labor strikes, terrorism, and cyber incidents

What are the latest HAE SEC filings in 2026?

HAEMONETICS CORP (HAE) has filed a 10-K annual report on May 21, 2025, a 10-Q quarterly report on February 5, 2026, an 8-K current report on May 1, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did HAE file its most recent 10-K annual report?

HAEMONETICS CORP (HAE) filed its most recent 10-K annual report on May 21, 2025. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view HAE 10-Q quarterly reports?

HAEMONETICS CORP (HAE)'s most recent 10-Q quarterly report was filed on February 5, 2026. SignalX displays every HAE 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has HAE filed recently?

HAEMONETICS CORP (HAE)'s most recent 8-K was filed on May 1, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find HAE insider trading activity (Form 4)?

SignalX aggregates every HAE Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does HAE file with the SEC?

HAEMONETICS CORP (HAE) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new HAE filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for HAEMONETICS CORP (HAE).

What is HAE's SEC CIK number?

HAEMONETICS CORP (HAE)'s SEC CIK (Central Index Key) number is 313143. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 313143 to look up all HAE filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find HAE return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from HAEMONETICS CORP (HAE) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.